GSK: Positive momentum and buyback program led to price holding above key averages

Traders Union
All News
Financial News
GSK rises 0.47% to GBX 1,813.50

Highlights

GSK repurchased 248,000 of its own ordinary shares through BNP Paribas SA as part of its ongoing share buyback program.
The transaction aligns with GSK's previously stated capital allocation strategy, reinforcing its commitment to returning value to shareholders.
No additional major corporate actions were reported alongside the buyback announcement.

Share buyback reinforces capital return commitment under existing program

GSK has announced the repurchase of 248,000 of its own ordinary shares as part of its ongoing share buyback program, conducted through BNP Paribas SA. This transaction aligns with the company's previously stated capital allocation strategy and demonstrates its ongoing commitment to returning value to shareholders. No additional major corporate actions were reported.

Trend strength confirmed as oscillators diverge near resistance levels

Momentum signals are broadly positive, with the daily MACD at a strong buy and ADX supporting trend strength. RSI and CCI both remain in bullish territory, while Stoch RSI is currently oversold, suggesting a need for caution in the near term as oscillators diverge. BBP points to buyer dominance, and although the Awesome Oscillator is neutral, it does not counter the prevailing bullish trend. Ichimoku Kijun at GBX 1,800 serves as dynamic support, while resistance is found near the MA-5 at GBX 1,816 and at the round level of GBX 1,820.

Further gains likely as technicals indicate high upside probability

For the coming week, the expected trading range is GBX 1,820 to GBX 1,845, reflecting the typical volatility band relative to current levels. There is a high probability (over 80%) of further price gains as weekly technical indicators such as RSI, ADX, MACD, and MA-50 remain strongly bullish. The baseline expectation is continued sideways consolidation within this corridor; a sustained move above GBX 1,845 could spur additional bullish momentum, while any weakness below GBX 1,820 would increase downside risk to the short-term uptrend.

Anton Kharitonov, analyst at Traders Union, sees GSK’s technicals as firmly bullish, supported by positive momentum and the recent share buyback activity. However, he notes the divergence in oscillators and possible short-term overextension. The analyst remains cautious, expecting price to consolidate between GBX 1,820 and GBX 1,845, with any drop below support raising downside risk. "Base case is sideways movement within the current corridor — I stay defensive until GBX 1,845 is cleared with conviction."

Previously it was reported that GSK remained firmly above its key moving averages, with bullish signals from MACD and ADX reflecting strong trend momentum and support from oscillators such as RSI. Despite these positive technicals, the price consolidated in a narrow range and overbought conditions were flagged, suggesting sideways action could persist before any decisive move — overbought conditions were flagged.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.